CAR-T therapy for myelofibrosis

Current understanding

To be populated as evidence accumulates.

2026-06-24 — Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.: cross-connection with cd4car-t-cell-therapy-cmml: Both represent CAR-T cell immunotherapy approaches in MPN/MDS-MPN overlap diseases, with CD4CAR extending the CAR-T paradigm from myelofibrosis into CMML by targeting CD4+ monocytic cells. (novelty: 4)
May 1, 202 — Mutant calreticulin–directed immunotherapies in myeloproliferative neoplasms: cross-connection with inca033989-mpn: Both target the mutant CALR C-terminal neoepitope; the review frames them as parallel modalities (antibody vs. CAR-T) against the same neoantigen, with antibodies further along clinically. (novelty: 3)
2026-05-15 — Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm: cross-connection with tcr-based-immunotherapy-mpn: Both represent adoptive cell therapy approaches in MPN; TCR-based strategy is antigen-discovery stage while CAR-T is further along, suggesting complementary immunotherapy axes. (novelty: 4)